login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Fluoroscopy times and radiation exposure during renal denervation compared to coronary procedures


Thursday, 15 Mar 2012 10:36

A retrospective analysis conducted in Germany shows that fluoroscopy times and radiation exposure in patients undergoing renal denervation are similar to those in patients undergoing routine diagnostic catheterisation with elective percutaneous coronary intervention but lower than in patients undergoing emergency intervention. The results were showed in a poster presentation at ISET in Miami, USA.


Ionising radiation carries an oncogenic risk which is linearly related to the dose and is closely related to procedural time. An estimation of the effective dose can be obtained from the measurements of the dose-area product, which is a measure of stochastic risk and a potential quality indicator,” the authors, led by Frank Himmel, Medizinische Klinik II, Universitätsklinikum Schleswig-Holstein, Lübeck, wrote.


The aim of the study was to assess fluoroscopy time, radiation exposure (dose area-product) and contrast dye consumption in patients undergoing renal denervation to treat medically resistant hypertension in comparison to diagnostic catheterisation and percutaneous coronary intervention.


A retrospective analysis of renal denervation therapy and adult cardiac percutaneous procedures (consecutive patients between January to May 2011 undergoing coronary angiography and ventriculography) was carried out to determine procedural characteristics and the dose-area product. The investigators identified four groups: group 1 (n=790, coronary angiography); group 2 (n=141, elective percutaneous coronary intervention in stable patients); group 3 (n=160, emergency percutaneous coronary intervention in acute coronary syndrome patients), group 4 (n=54, patients undergoing renal denervation). Dose-area product meter attached to the X-ray unit was used for the estimation of the radiation dose received by the patient during the procedures. In average renal denervation therapy consisted of 6–9 bilateral ablations spots.


The results showed that in the renal denervation group fluoroscopy time, dose-area product and contrast dye consumption were 10±1sec, 4878±456cGy cm2 and 141±6mL, respectively. In the elective percutaneous coronary intervention, fluoroscopy time was 11±1sec, dose-area product was 7457±421cGy cm2, and contrast dye consumption was 136±5mL. In emergency percutaneous coronary intervention patients, fluoroscopy time was 12±1sec, dose-area product was 9046±482cGy cm2, and contrast dye consumption was 213±6±5mL.


The authors concluded that the radiation dose varies substantially across different types of procedures and up to tenfold within the same procedure. “The enhanced knowledge of radiation dose might help the cardiologist to implement radiation sparing procedures minimising patient and operator radiation hazards in renal denervation,” they wrote.

 

 

Results (mean±standard error of the mean)

Body weight (kg)

Fluoroscopy time (sec)

Dose-area product (cGy cm2)

CDC (mL)

Group 1 (coronary angiography)

82±1

5±0.6

3514±99

99±1

Group 2 (elective PCI)

84±1

11±1*

7457±421*

136±5*

Group 3 (emergency PCI)

82±1

12±1*

9046±482*+

213±6*+

Group 4 (renal denervation)

92±3*

10±1*

4878±456*

141±6*

 

* p<0.05 vs. group 1, + p<0.05 vs. group 2




Add New Comment

Related Items


Most popular


Medtronic completes acquisition of Covidien
Tuesday, 27 Jan 2015
Under the terms of the acquisition agreement, Medtronic Inc and Covidien plc are now combined under Medtronic plc. Medtronic completes acquisition of Covidien

Transapical TAVI can be performed with comparable results to transfemoral TAVI in high-volume centres
Friday, 16 Jan 2015
Results from a registry of 1,000 patients undergoing transcatheter aortic valve implantation (TAVI) in a high-volume centre do not indicate a significant difference in the rates of short- and long-... Transapical TAVI can be performed with comparable results to transfemoral TAVI in high-volume centres

Arteriovenous anastomosis creation brings blood pressure down
Friday, 06 Feb 2015
The ROX CONTROL HTN, an international randomised controlled trial, published online ahead of print in The Lancet in late January, has demonstrated that creation of a central arteriovenous anastomosis ... Arteriovenous anastomosis creation brings blood pressure down

Features


Exploring new transcatheter options for the mitral valve
Thursday, 19 Feb 2015
Anson Cheung (University of British Columbia, St. Paul’s Hospital, Vancouver, Canada) speaks to Cardiovascular News about the potential benefits of transcatheter mitral valve implantation. Exploring new transcatheter options for the mitral valve

Tailoring dual antiplatelet therapy duration for an individual patient
Tuesday, 03 Feb 2015
Guillaume Cayla explores how the duration of DAPT may be tailored after careful evaluation of both bleeding and ischaemic risk, taking into consideration the type of the device implanted. Tailoring dual antiplatelet therapy duration for an individual patient

Profiles


Sunil Rao
Thursday, 23 Oct 2014
Sunil Rao speaks to Cardiovascular News about his career highlights, including his research into ... Sunil Rao

Azeem Latib
Wednesday, 24 Sep 2014
Azeem Latib (senior interventional cardiologist, San Raffaele Hospital and EMO-GVM Centro Cuore C... Azeem Latib

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions